Kornimate/medical-research-clean huggingface dataset:
telehealth exercise intervention to improve physical function and frailty in multiple myeloma survivors

Conditions: Plasma Cell Myeloma

Summary: this clinical trial examines a telehealth exercise intervention in improving physical function and frailty in multiple myeloma survivors. the exercise program uses a telehealth platform (delivered by smart phones, tablets, or computers) to view pre-recorded exercise videos on coordination, posture, stretching, balance, and resistance/aerobic (cardio) training. frailty includes being underweight, slow walking speed, exhaustion, low physical activity, and weakness. participating in an exercise program may help improve patient's physical function and strength.

primary objective: i. determine the effects of an 8-week telehealth exercise intervention on physical function as assessed by the short physical performance battery (sppb) test (aim 1) secondary objectives: i. determine the effects of an 8-week telehealth exercise intervention as assessed using a 5-scale frailty index: body mass index (self-report), tiredness (questionnaire), level of physical activity (self-report), gait speed (sensors), and muscular strength (hand grip dynamometer) (aim 2). ii. determine the sustainability of the intervention on physical function and frailty at week 17 (aim 3). outline: patients are randomized to 1 of 2 arms. arm a: patients undergo home-based exercise program 3 times per week for 8 weeks. patients complete questionnaires at baseline (before 1 week) and at weeks 9 and 17. arm b: patients complete questionnaires at baseline and at week 9 and 17. patients continue maintaining current activities of daily living and do not participate in any exercise program. patients may then participate in home-based exercise program 3 times per week for 8 weeks.

Eligibility criteria:
inclusion criteria: * diagnosed with multiple myeloma * \>= 18 years old * self-reported as pre-frail or frail (i.e. fried criteria: clinically underweight and exhibiting exhaustion, low energy expenditure, slow walking speed, and muscle weakness), with the presence of 2/5 indices classified as pre-frail and \>= 3/5 indices classified as frail * has undergone autologous stem cell transplant (asct) within 30 and 180 days prior to registration * physically able and willing to complete all study procedures * english-speaking exclusion criteria: * have clinically significant/active cardiovascular disease (e.g. unstable angina, uncontrolled arrhythmia, etc.) * have contraindications to exercise (acute infectious disease or unstable bone lesions) * currently recovering from a recent injury or have been physically injured in the past 6 months, in which participation in rigorous exercise may not be appropriate * participate in regular, structured exercise (\> 60 minutes/week) * female patients who are pregnant or planning to become pregnant
metabolism of branched-chain amino acids in monocyte/macrophage during sepsis

Conditions: Sepsis Syndrome

Summary: the current project was designed to examine the metabolic level of branched-chain amino acids in plasm and monocyte/macrophage, and its role in immune dysfunction during sepsis.

in this study, the investigators will collect the peripheral blood of 1,3,7,14 day after diagnose of sepsis. then, the concentration of branched-chain amino acids(bcaas) in monocytes and plasma, and the expression of bcaas metabolic enzymes in monocytes will be determined. additionally, the inflammatory cytokines, e.g., interleukin-1β (il-1β), tumor necrosis factor-α (tnf-α), interleukin-10 (il-10）, the chemokines macrophage inflammatory proteins 1α and 1β (mip-1α and 1β) in the peripheral blood and the phagocytic function of monocytes will also be detected. the current project was designed to examine the metabolic level of branched-chain amino acids in plasm and monocyte/macrophage, and its role in immune dysfunction during sepsis.

Eligibility criteria:
inclusion criteria: * patients diagnosed with sepsis, with or without type 2 diabetes * healthy volunteers exclusion criteria: * patients with immunodeficient diseases * patients who accept glucocorticoid or immunosuppressant * patients with an age younger than 18 years * patients who cannot provide the informed consent
percutaneous vs conventional radiofrequency applications for the treatment of knee osteoarthritic pain

Conditions: Percutaneous; Conventional; Radiofrequency; Knee Osteoarthritis; Pain

Summary: this study aims to compare percutaneous and conventional radiofrequency applications for the treatment of knee osteoarthritic pain.

osteoarthritis (oa) is a progressive degenerative joint disease that affects the joint cartilage and surrounding tissues. it mostly affects the weight-bearing joints, and in this respect, the knee joint is one of the joints that is most affected. radiofrequency (rf) treatment has been used for several painful conditions such as trigeminal neuralgia, cancer pain, and spinal pain. to destroy nerves or disrupt the transmission of pain signals, originally using producing heat lesions, rf current is applied to the trigeminal ganglion, the spinothalamic tracts of the spinal cord, the medial branches of posterior rami, and the dorsal root ganglion. in addition to these, there have been a few attempts to apply rf current for the treatment of painful conditions of joints of the extremities. percutaneous radiofrequency ablation (rfa) of articular sensory nerves has recently emerged as an attractive and minimally invasive approach to treat chronic pain due to large-joint osteoarthritis in select patients.

Eligibility criteria:
inclusion criteria: * age \> 18 years old. * both sexes. * patients with knee osteoarthritis. * previous conservative treatments longer than 3 months. * visual analog scale (vas)≥ 4. * radiological osteoarthritis grades 3 and 4 according to the kellgren-lawrence grading system (0 = none, 1 = doubtful, 2 = minimal, 3 = moderate, and 4 = severe). exclusion criteria: * prior knee surgery. * allergies to local anesthetics. * connective tissue diseases affect the knee. * serious neurologic or psychiatric disorders. * injection with steroids or hyaluronic acids during the previous 3 months. * history of septic arthritis. * sciatic pain. * cardiac pacemaker users. * anticoagulant medications. * prior electroacupuncture treatment.
simulation-based training for ultrasound-guided perineural catheter insertion

Conditions: Pain Management; Simulation; Training; Ultrasonography

Summary: this study will determine the efficacy of a teaching program incorporating hybrid simulation in training practicing anesthesiologists on ultrasound (us)-guided continuous peripheral nerve block (cpnb). this study will also examine the extent of practice change following participation in a regional anesthesia teaching program incorporating hybrid simulation. in addition, this study will assess remaining obstacles to incorporating the use of us-guided perineural catheters through identifying potential future interventions and "tool-kits" for setting up perineural catheter programs.

study subjects will complete a pre-course survey to assess prior experience then participate in a standardized one-day workshop comprised of two sessions; 1) a didactic lecture and model scanning session and 2) a simulation session. quantitative and qualitative assessments will be performed using video analysis by two blinded reviewers after equipment orientation (baseline), following first session, and following second session. performance times, number of attempts, and composite scores for procedural performance and ergonomics will be analyzed within and between groups. every 3 months for one year, subjects will be surveyed to assess implementation of pnb in practice and identify remaining barriers.

Eligibility criteria:
inclusion criteria: * anesthesiologists in practice ten years or more; active board certification (american board of anesthesiologists); active license to practice medicine in california; and willingness to spend one full day (8 hours) participating in the standardized workshop and undergo interval survey and interview follow-up for one year. exclusion criteria: * formal training (e.g., post-graduate fellowship) in regional anesthesia; current practice includes the routine performance of us-guided pnb (≥10 blocks per month); or visual, hearing, or other communication impairment that would interfere with video recording or require substantial deviation from the standardized teaching curriculum.

Keywords: simulation ultrasound perineural infusion continuous peripheral nerve block
clinical trial of comparative study of gb221 pharmacokinetics

Conditions: Metastatic Breast Cancer

Summary: the primary objective is to assess the safety of a single dose of gb221 compared to herceptin® when administered as a single iv injection at a dose of 8 mg/kg. the secondary objective of the study is to assess the pharmacokinetics of gb221 compared to herceptin®.


Eligibility criteria:
inclusion criteria: to be enrolled in the study, subjects must meet the following criteria 1. males aged 18 to 45 years. 2. healthy as judged by medical examination and medical history, and clinical chemistry and hematology screening. 3. body weight within the normal range for height (bmi between 19.0 and 29.0, inclusive) up to a maximum of 90 kg. 4. normal or non-clinically significant ecg. 5. normotensive (systolic: 90 - 140; diastolic: 50 - 90 mm hg, inclusive) and heart rate (40 -100 bpm, inclusive). 6. willingness to give written and informed consent prior to any studyrelated procedures being conducted exclusion criteria: subjects will be ineligible for the study if any of the following criteria apply: 1. receipt of any investigational agent or drug within 4 weeks of entry to the study. 2. use of any medicine - prescription, over-the-counter or herbal - in the 7 days prior to the treatment day and until 12 weeks after the treatment day. 3. donation of blood (or loss of blood) greater than 400 ml within 3 months of the study. 4. clinically significant drug allergy or sensitivity to any medication. 5. a history of chronic or recurrent infections. 6. a recent history of surgery. 7. history or presence of malignancy (with the exception of successfully treated basal cell carcinoma). 8. inability to communicate or cooperate with the principal investigator because of english language difficulties or poor mental development. 9. a history (within the last 5 years) or evidence of alcohol or drug abuse (excepting tobacco use less than 10 cigarettes per day). 10. a positive urine test for drugs of abuse or alcohol either at screening or on the day of admittance for drug administration. 11. vaccination of any type within the previous month. 12. a history of major psychiatric illness (such as bipolar disorder, schizophrenia or persistent major depression). previous minor depression/adjustment disorder is acceptable if currently asymptomatic. 13. consumption of more than 3 standard drinks per day, and not able to abstain from alcohol totally within 24 hours of dose administration. 14. presence of current infection with tuberculosis, hepatitis b, hepatitis c or hiv. 15. history of asthma or other chronic respiratory disease in the past 5 years. 16. history of neurological or neuromuscular disease. 17. history of hypertension or cardiovascular disease, including congestive heart failure and cardiomyopathy or a clinically significant echocardiogram finding at the screening visit. 18. history of bladder or urethral disease. 19. smoking cigarettes \> 10 per day. 20. any other condition which in the view of the principal investigator is likely to interfere with the study or put the subject at risk.
evaluation of topical antipsoriatics in the psoriasis plaque test

Conditions: Psoriasis Vulgaris

Summary: the purpose of this study is to evaluate the efficacy of the topical therapies protopic and advantan as well as their combination against placebo in a psoriasis plaque test

daily psoriasis plaque tests for two weeks and optical coherence tomography (oct) and 20-mhz-ultrasound on day 0 and day 11, 10 days post end of treatment and 20 days post end of treatment

Eligibility criteria:
inclusion criteria: * patients older than 18 years * negative urine pregnancy test * written informed consent * good compliance exclusion criteria: * patients less than 18 years * pregnant patients * patients with renal insufficiency, liver diseases * patients who received systemic antipsoriatic treatment or uv treatment less than 4 weeks prior to study * patients who used topical antipsoriatics within two weeks prior to study * immunosuppressed patients

Keywords: topical therapy psoriasis plaque test
a phase i study of continuous infusion immunotoxin igg-rfb4-smpt-dga in refractory cd22 positive b-cell lymphoma

Conditions: B Cell Lymphoma

Summary: patients with cd22(+) b-cell lymphomas will be treated with escalating doses as a 192 hr infusion of immunotoxin in a phase i study to determine dose limiting toxicity evidence of response.

patients with cd22(+) b-cell lymphomas will be treated with escalating doses as a 192 hr infusion of immunotoxin in a phase i study to determine dose limiting toxicity evidence of response.

Eligibility criteria:
patients with a histologic diagnosis confirmed from a pretreatment biopsy at the laboratory of pathology, nci of one of the following entities: diffuse small lymphocytic lymphoma; follicular, small cleaved cell lymphoma; follicular, mixed small cleaved and large cell lymphoma; follicular large cell lymphoma; diffuse, intermediately differentiated lymphocytic lymphoma; diffuse, small cleaved cell lymphoma; diffuse, mixed small and large cell lymphoma; diffuse, large cell lymphoma; large cell immunoblastic lymphoma; small noncleaved cell lymphoma. presence of cd22 antigen on at least 30 percent of tumor cells. presence of objectively measurable sites of disease. bone marrow positivity and circulating tumor cells in the peripheral blood will be considered evaluable but not measurable disease. no patients with purely b-cell lymphosarcoma cell leukemia without nodal or soft tissue involvement. no patients with b-cell chronic lymphocytic leukemia, or b-cell or pre-b-cell acute lymphocytic leukemia, and hairy cell leukemia. patients with objectively measurable disease outside a radiation port or disease which has clearly progressed within a radiation port. hiv negative. no cns disease. no pulmonary parenchymal disease. pleural effusions or ascites may be present. patients with progression of disease despite at least one standard combination chemotherapy regimen. no chemotherapy for at least two weeks prior to entry. patients who do not desire or are not candidates for autologous or allogeneic bone marrow transplantation procedures. life expectancy of at least 3 months creatinine clearance greater than 60 cc per minute. total bilirubin less than 1.5 mg/dl. sgpt less than 2 times the upper limit of normal. albumin greater than 75 percent of the lower limit of normal. if prior treatment with doxorubicin, the radionuclide or echocardiogram ejection fraction shall be at least 35 percent. performance status 0-2. not in need of current radiation therapy to alleviate local problems. no prior exposure to murine antibodies. no need for current corticosteroid treatment.

Keywords: antigen modulation pharmacokinetics ricin a chain
steroid and behaviour changes under metformin

Conditions: Autistic Disorder

Summary: background based on various suggestions, social behavior is mediated by a change in steroid hormones. these have diverse effects on the (neuro-)development during critical stages, whereby especially androgen and insulin metabolism seem to play a key role. various lines of evidence indicate that metformin could influence and improve the symptoms of social withdrawal. therefore, the investigators will analyze urinary samples of patients before and after treatment with metformin to elucidate the changes in steroid hormone profiles and measure changes in social behavior to examine a potential correlation. material \& methods steroid hormone analysis including the most prominent androgen, estrogen, progesterone, aldosterone, corticosterone, cortisone and cortisol metabolites analyzed with gas chromatography mass spectrometry and a questionnaire (autism-spectrum quotient) will be performed prior to and after 12-weeks metformin treatment. discussion it is likely, that due to different pathophysiological mechanisms such as an effect on respiratory chain in mitochondria or via amp activated protein kinase a general reduction of total androgens will be detected prior versus post metformin treatment. the encompassing measurement of steroid hormones will allow to detect influences on different metabolites and in consequence enzyme activities. the potential changes prior versus post shall give hints concerning the involvement of specific cascades involved, with potential pharmacological targets for future research.


Eligibility criteria:
inclusion criteria: * patients with type 2 diabetes mellitus and an indication for metformin according to the american diabetes association (american diabetes association, 2021a) starting a new metformin treatment. the main marker will be fasting plasma glucose levels of 7.0mmol/l and/or hba1c 6.5% (american diabetes association, 2021a). * written informed consent. exclusion criteria: * patients under 18 years of age. * clinically significant concomitant disease (e.g. advanced renal failure, hepatic dysfunction, neoplasia). * significant musculoskeletal disease. * active infection during sample collection. * immunosuppressive medical therapy. * hormonal/steroid treatment. * pregnancy. * psychiatric disease and known social behavior altering medication (e.g. antipsychotic medication). * known or suspected malcompliance, drug or alcohol abuse. * inability to follow the procedures of the study, e.g. due to insufficient language skills, severe dementia. * life-expectancy \< 6 months. * poor tolerability to metformin treatment with following treatment discontinuation within duration of follow up.

Keywords: steroid hormones gc-ms urine analysis androgens autism spectrum disorders
autologous hematopoietic stem cell transplantation for refractory lupus nephritis

Conditions: Lupus Nephritis

Summary: in this study, we aimed to evaluate the long term efficacy, remission, survival and safety of autologous hematopoietic stem cell transplantation in patients with refractory lupus nephritis. this is an single arm, non-randomized study. patients who were diagnosed with relapsed and refractory lupus nephritis would included in this study. refractory lupus nephritis is defined as no response to at least one type of immunosuppressant therapy (including corticosteroids, cyclophosphamide, tacrolimus, mycophenolate mofetil and cyclosporine) for more than six months, or relapse during the period maintenance therapy with kidney pathological transformation or persistently positive antibodies. close observation was carried out at stem cell harvest, at transplantation, at 3, 6, 12, 18, and 24 months and then once a year after autologous stem cell transplantation. 20-30 cases will be included in this study.

treatment plan: peripheral blood stem cells were mobilized with cyclophosphamide (2.0 g/m2) for 2 days and granulocyte colony-stimulating factor (g-csf) at 5-10 μg/kg per day was administered when the level of peripheral leucocytes was \ 2×10\^6/kg and mononuclear cells \> 2×10\^8/kg. the graft was preserved at a temperature of -196 ℃ for further use. the conditioning regimen consisted of intravenous cyclophosphamide (40 mg/kg/day × 4 days) 5 days before transplantation (a total dose 160 mg/kg) and rabbit antithymocyte globulin (atg) (2.5mg/kg/day × 3 days) 4 days before transplantation. the dose of cyclophosphamide and atg could be reduced according to the patients' condition. methylprednisolone (80-500 mg/day) was administered through intravenous drip at the same time with atg to reduce anaphylaxis. the incidence of drug-related complications was decreased by hyperhydration (the volume of infusion liquid is 50 ml/kg/day), urine alkalization (infusion of sodium bicarbonate 250ml/day), and anti-emetic medication. g-csf (0.5 μg/kg/d) was administered to each patient beginning the day after stem cells reinfusion until the level of absolute peripheral neutrophil count was consecutively higher than 1.0 × 10\^9/l.

Eligibility criteria:
inclusion criteria: * 1. diagnosed with relapsed and refractory lupus nephritis; 2. ages from 14 - 45 years old; 3. serum creatinine \ 50%; 6. subjects (or their legal representatives) must signed an informed consent document. exclusion criteria: * 1. active infection; 2. known or suspected hypersensitivity to ctx or atg; 3. subjects suffering from uncontrolled or severe cardiovascular disease; 4. subjects suffering from serious physical disease and mental illnesses.
comparison of quadratus lumborum intramuscular and transmuscular in postoperative pain

Conditions: Pain, Postoperative; Pain, Acute; Cesarean Section Complications

Summary: acute pain is reported in approximately 80% of patients undergoing postoperative care for various types of surgical procedures in the united states. another study reported patient postoperative pain intensity with 75% with severe pain in the first 1 to 2 postoperative days and 38% reporting moderate to severe pain at 14 postoperative days. several modalities have been used as the standard for the management of pain postoperative c-sections. one of the postoperative analgesic modalities for sc is quadratus lumborum block (qlb). this technique has advantages in relieving postoperative pain after c-section because it is considered to be able to relieve visceral pain as well as somatic pain. the transmuscular qlb (qlbt) approach is one of the most frequently used. this technique was found to be effective with regard to the distribution of analgesics to the paravertebral spaces which is the hallmark of qlb. however, this technique was found to be difficult to perform. difficulties were reported related to the position of the procedure i.e. lateral or sitting position.


Eligibility criteria:
inclusion criteria: * underwent c-section with subarachnoid block * aged 18-35 years old. * asa preoperative physical status 1-2 exclusion criteria: * coagulopathy * anatomic abnormalities of the abdomen * history of allergy to local anesthesia * history of hyperalgesia * history of drug abuse (sedatives, opioids, paracetamol, or other pain relievers) * require postoperative intensive care * refuse to participate in research.